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Background: Breast cancer (BC) is considered to be one of the most important causes of death worldwide, and it
affects the Iranian female population a decade earlier than female in other parts of the world. Human telomerase
reverse transcriptase (hTERT) is a main subunit of the telomerase complex. MNS16A is located downstream of the
hTERT gene and is recognized as the regulator of hTERT promoter activity. The aim of the present study was to
access the possible impact of hTERT variants on BC risk in an Iranian population in southeast Iran.
Methods: A total of 491 subjects including 266 BC patients and 225 healthy women participated in the study.
Polymerase chain reaction (PCR) was used to genotype the MNS16A variable number of tandem repeats and 177 bp
ins/del polymorphisms in the hTERT gene. PCR-RFLP and ARMS-PCR were used to genotype hTERT rs2736098 and
2735940, respectively. The association between genotypes and BC was assessed by computing the odds ratio
(OR) and 95% confidence intervals (95% CI) from logistic regression analyses. A p-value of <0.05 was considered
statistically significant.
Results: The MNS16A genotype frequency distribution in BC patients was: LL, 43.2%; LS, 51.1%; and SS, 5.7%,
and in controls: LL, 29.5%; LS, 68.3%; and SS, 2.2%. The LS genotype decreased the risk of BC compared with LL
(OR = 0.51, 95% CI = 0.35-0.75, p < 0.001). The hTERT 177 bp ins/del polymorphism was not polymorphic in our
population. All subjects had the ins/ins genotype. Our findings indicate that the MNS16A genotype and hTERT
rs2736098 variant were associated with BC risk in the study. We also showed that the rs2736098 A/G polymorphism
increased the risk of BC (OR = 1.80, 95% CI = 1.12-2.88, p = 0.017, AG vs AA; OR = 1.80, 95% CI = 1.06-3.06, p = 0.033,
GG vs AA; OR = 1.87, 95% CI = 1.19-2.94, p = 0.006, AG + GG vs AA). No significant association was found between the
rs2735940 C/T variant and BC.
Conclusion: Our findings indicate that the MNS16A genotype and the hTERT rs2736098 variant influence the risk of BC
in an Iranian population in southeast Iran.
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Many women are diagnosed with breast cancer (BC)
each day worldwide. Globally, BC may be considered the
most common cancer among females and it is also the
leading cause of cancer-related deaths in many countries
[1]. BC is recognized as an important health care prob-
lem worldwide, affecting approximately 1 million women
annually [1-3]. BC is also reported to be one of the most
frequent malignancies among Iranian women, and it
comprises 21.4% of female cancers in this population
[4]. Interestingly, it has been reported that BC affects
Iranian women about a decade earlier than women in
Western countries [5], which highlights the importance
of research on BC in the Iranian population. Several
different factors are involved in BC pathogenesis, but its
exact etiology is complicated and is not clearly identified.
Our previous investigations provided solid evidence that
genetic factors play important roles in the pathogenesis
and progression of this malignancy in the population in
southeast Iran [6-11].
Telomeres are repeat sequences of TTAGGG at the
end of linear chromosomes and are responsible for pro-
tecting against loss of genetic information during the
process of cellular division [12,13]. Repeated cell cycles
cause telomere shortening, drive the cells into the senes-
cence condition, and finally trigger programmed cell
death I, which potentially protects the cells against
genomic instability and carcinogenesis [14]. Therefore,
telomeres could be considered to be a key factors in
cellular genomic maintenance and a potential candidate
for carcinogenesis [12]. Human telomerase reverse tran-
scriptase (hTERT) is a catalytic subunit of the telomerase
[15], which together with the telomerase RNA component
(TERC), is the main subunit of the telomerase complex
[16]. Human TERT (hTERT) is located in 5p15.33 [17]
and consists of 16 exons. Telomerase is a ribonucleo-
protein that maintains integrity in the telomere regions,
which subsequently shorten each replication cycle [18,19].
Without telomeres, genomes would increasingly lose their
information and would be truncated after cell division
because enzymes that replicate DNA cannot continue
duplication all the way to the chromosome ends [20]. It
has been proposed that genetic instability is a driving
force for transformation of normal cells into malignant
cells during carcinogenesis [21].
MNS16A is known as a polymorphic tandem repeat
minisatellite that is located downstream of the hTERT
gene and it was first shown to be involved in promoter
activity in lung cancer cell lines [22]. The variants that
contain short tandem repeats have more effective pro-
moter activity than those with long repeats, highlighting
the importance of the number of tandem repeats in the risk
of lung cancer. Many other groups have investigated the
role of MNS16A in the etiology of different malignanciesincluding cerebral [23], lung [24], breast [25], and colo-
rectal cancer [26], but their results were inconsistent.
Because hTERT is the key molecular complex that
maintains telomere stability, genetic variants in hTERT
might impact on the risk of BC. However, considering
the important role of MNS16A in hTERT gene promoter
activity, we evaluated the MNS16A genotype and the
impact of hTERT polymorphisms on BC susceptibility in
a sample of the Iranian population.
Methods
Patients
This case-control study enrolled 266 pathologically con-
firmed BC patients who were referred to the Ali Ebneh
Abitaleb hospital (Iran) and 225 age- and population-
matched healthy women who participated in a screening
project for metabolic syndrome; they were unrelated to
the patients and had no history of any type of cancer.
The clinicopathologic characteristics of the patients are
summarized in Table 1. Ethical approvals for recruit-
ment were obtained from the local Ethics Committee of
Zahedan University of Medical Sciences, and informed
consent was obtained from all patients and healthy indi-
viduals. Blood samples from patients and healthy con-
trols were collected in EDTA-containing tubes and DNA
was extracted using the salting out method, as described
previously [27]. The quality of the isolated DNA was
verified using electrophoresis on 1% agarose gel, quanti-
tated spectrophotometrically and stored at -20°C until
further use.
Polymerase chain reaction
Polymerase chain reaction (PCR) was used to genotype
the MNS16A variable number of tandem repeat polymor-
phisms with the primer set, as previously reported [22].
The forward and reverse primer sequences were 5′-
AGGATTCTGATCTCTGAAGGGTG-3′ and 5′-TCTGC
CTGAGGAAGGACGTATG-3′, respectively. PCR was
performed using 2X Prime Taq Premix (Genet Bio, Korea).
The amplification procedure consisted of an initial de-
naturing step for 5 min at 95°C followed by 30 cycles for
30 s at 95°C, 20 s at 67.5°C, and 17 s at 72°C, as well as a
final extension step for 10 min at 72°C. The PCR products
were visualized on 3% agarose gel containing 0.5 μg/ml
of ethidium bromide (Figure 1a) and genotypes were
assigned as previously reported [22]: the 243 bp and
272 bp bands were classified as the short (S*) allele, and
the 333 bp and 302 bp bands were classified as the long
(L*) allele, thus defining the MNS16A genotypes as L*/L*,
L*/S* and S*/S*.
hTERT 2736098 genotyping was accomplished using
RFLP. The forward and reverse primers were 5′AGG
ACGCGTGGACCGAGTGA-3′ and 5′- GGAACCCAG
AAAGATGGTCTC-3′, respectively. In each 0.20 ml
Table 1 Clinical and pathological characteristics of breast
cancer patients
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each primer and 10 μl of 2X Prime Taq Premix (Genet
Bio, Korea) and 7 μl ddH2O were added. The PCR
conditions were set as follows: 95°C for 5 min, 30 cycles
of 95°C for 30 s, 67°C for 30 s, and 72°C for 28 s and
a final extension step of 72°C for 10 min. The PCR
product (10 μl) was digested using Bsp120I restriction
enzyme. The G allele was digested and produced137 bp and 187 bp fragments while the A allele was
undigested and produced a 324 bp fragment (Figure 1b).
hTERT 177 bp insertion/deletion genotyping was per-
formed using PCR with forward (5′-GACCATCCTGG
ACTGATGGC-3′) and reverse (5′-AGGGGTGAACAA
TGGCGAAT-3′) primers, which can produce 366 bp
and 189 bp insertion and deletion alleles, respectively.
The PCR cycling conditions were 95°C for 5 min, 30 -
cycles of 95°C for 30 s, 66°C for 30 s, and 72°C for 26 s
and a final extension step of 72°C for 10 min. The PCR
products were verified on 2% agarose gels containing
0.5 μg/ml ethidium bromide, and observed under UV
light (Figure 1c).
The hTERT rs2735940 polymorphism was genotyped
using the amplification refractory mutation system poly-
merase chain reaction (ARMS-PCR) method. The primer
sequences were as follows: generic primer, 5′-CGGCAAA
CACTGAAATGCTA-3′; T allele, 5′-GGGATTTCTAGA
AGAGCGACAT-3′; and C allele, 5′-GGGATTTCTAGA
AGAGCGACAC-3′. The product size for the allele was
197 bp. Beta-2 microglobulin (B2MF: 5′-TGTAAACAC
TTGGTGCCTGATATAGCTTGA-3′, B2MR: 5′-CATCA
GTATCTCAGCAGGTGCCACTAATCT-3′), which pro-
duces 574 bp fragments, was used as an internal control.
In each 0.20 ml reaction solution, 1.3 μl of genomic
DNA (~100 ng/ml), 0.5 μl of each primer and 10 μl of
2X Prime Taq Premix (Genet Bio, Korea) and 6.7 μl
ddH2O were added. The PCR cycling condition was an
initial denaturation at 95°C for 5 min followed by 30 -
cycles of 30 s at 95°C, annealing temperature for 23 s
at 60°C, and 30 s at 72°C, with a final extension of 72°C
for 10 min. The PCR products were verified on 2%
agarose gels containing 0.5 μg/ml ethidium bromide,
and observed under UV light (Figure 1d). Product sizes
were 252 bp for either of the Ins or Del alleles, and
574 bp for the internal control. The presence of a
252 bp allele-specific band, in conjunction with a
574 bp control band, was considered to be positive evi-
dence for each particular allele. The absence of an
allele-specific band and the presence of a control band
were considered to be evidence for the absence of an
allele (Figure 1d).Statistical analysis
Statistical analysis was performed using the statistical
software package SPSS 18. The association between
genotypes and BC were assessed by computing the
odds ratio (OR) and 95% confidence intervals (95%
CI) from logistic regression analyses. Haplotype ana-
lysis was performed using SNPStats software [28,29].
The Hardy–Weinberg equilibrium was tested for poly-
morphisms. A p-value of <0.05 was considered statis-
tically significant.
Figure 1 Photograph of DNA electophoresis for detection of hTERT polymorphisms. a: MNS16A. Lane 1, SS; lane 2, L/S; lanes 3 and 4, LL.
b: rs1718119. Lane 1, GA; Lane 2, GG; lane 3, AA. c: hTERT 177 bp ins/del polymorphism. Lanes 1, 2, 3 and 4, ins/ins. d: rs2735940. Lane 1, TC;
lane 2 TT; lane 3, CC. M = DNA marker.
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Results
The study groups included 266 BC patients with a mean
age of 48.9 ± 11.1 years and 225 healthy women with a
mean age of 50.0 ± 12.9 years. The patient group demo-
graphic information is summarized in Table 1. No sig-
nificant difference in age was found between the groups
(p = 0.306). The frequency distribution of the MNS16A
genotypes in BC patients was: LL, 43.2%; LS, 51.1%; and
SS, 5.7%, and the distribution in controls was: LL, 29.5%;
LS, 68.3%; and SS, 2.2% (Table 2). Our finding showed
that the L/S and L/S + S/S decreased the risk of BC
(OR = 0.51, 95% CI = 0.35-0.75, p < 0.001 and OR = 0.55,
95% CI = 0.38-0.81, p = 0.002, respectively) compared with
the L/L genotype.
The hTERT rs2736098 A/G variant was associated
with BC risk (Table 2). Our results indicated that AG
as well as GG and AG +GG increased the risk of BC
(OR = 1.80, 95% CI = 1.12-2.88, p = 0.017; OR = 1.80, 95%
CI = 1.06-3.06, p = 0.033 and OR = 1.87, 95% CI = 1.19-
2.94, p = 0.006, respectively) compared with the AA
genotype. The rs2736098 G allele increased the risk of
BC compared with the A allele (OR = 1.38, 95% CI =
1.06-1.78, p = 0.016). Our results also demonstrated that
the hTERT rs2735940 polymorphism was not associatedwith BC risk/protection, while the rs2735940 T allele
increased the risk of BC compared with the C allele
(OR = 1.35, 95% CI = 1.05-1.75, p = 0.020). The 177 bp ins/
del polymorphism was not polymorphic in our population
so that all patients and controls had the insertion allele for
the hTERT 177 bp ins/del polymorphism.
Haplotype analysis is shown in Table 3. Haplotypes
LCA and STA decreased the risk of BC compared with
LTG (MNS16A T/rs2735940 T/rs2736098 G). No signifi-
cant association was observed among the hTERT poly-
morphisms and clinicopathologic parameters, including
tumor stage, tumor grade, estrogen and progesterone
receptors (ER, PgR), tumor size, and human growth
factor receptor 2 (HER2) (Table 4).
Discussion
Telomeres are involved in maintaining genomic stability
[30]. In the current study, we investigated the impact of
hTERT variants on BC risk in a sample of the Iranian
population in southeast Iran. Our data demonstrated
that MNS16A LS and L/S + S/S decreased the risk of BC.
AG as well as GG and AG+GG increased the risk of BC
for the rs2736098 A/G polymorphism. The rs2736098 G
allele was associated with an increased risk of BC.
Although the hTERT rs2735940 C/T polymorphism
Table 2 The genotypes and allele distribution of hTERT variants in breast cancer patients and the control group
Variants Patients n (%) Controls n (%) OR (95% CI) p
MNS16A Genotype
L/L 115 (43.2) 66 (29.5) 1.00 -
L/S 136(51.1) 153(68.3) 0.51 (0.35-0.75) <0.001
S/S 15 (5.7) 5 (2.2) 1.72 (0.61-4.95) 0.460
L/S + S/S 151 (56.8) 158 (65.5) 0.55 (0.38-0.81) 0.002
Allele
L 366 (68.8) 285 (63.6) 1.00 -
S 166 (31.2) 163 (36.7) 0.79 (0.61-1.03) 0.090
rs2736098
AA 40 (15.8) 58 (26.1) 1.00 -
AG 140 (55.3) 113 (50.9) 1.80 (1.12-2.88) 0.017
GG 72 (28.5) 51 (23.0) 1.80 (1.06-3.06) 0.033
AG + GG 212 (83.8) 164 (73.9) 1.87 (1.19-2.94) 0.006
Allele
A 220 (43.7) 229 (51.6) 1.00 -
G 284 (56.3) 215 (48.4) 1.38 (1.06-1.78) 0.016
rs2735940
CC 45 (17.0) 39 (17.3) 1.00 -
CT 124 (47.0) 138 (61.3) 0.78 (0.48-1.28) 0.380
TT 95 (36.0) 48 (21.3) 1.72 (0.99-2.98 0.066
CT + TT 219 (83.0) 186 (82.6) 1.02 (0.64-1.64) 0.991
Allele
C 214 (40.5) 216 (48.0) 1.00 -
T 314 (59.5) 234 (52.0) 1.35 (1.05-1.75) 0.020
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T allele was significantly associated with BC risk. The
177 bp ins/del polymorphism was not polymorphic in our
population (all individuals were the ins/ins genotype).
Earlier studies showed that hTERT mRNA expression
is regulated by MNS16A in lung cancer [31], while stud-
ies in BC patients showed that MNS16A and BC risk
association are strongly related to the geographic area ofTable 3 MNS16A, rs2735940 and rs2736098 haplotype freque
and the control group
MNS16A rs2735940 rs2736098 Pat
L T G 0.2
L C G 0.1
L T A 0.1
L C A 0.1
S T A 0.1
S T G 0.0
S C A 0.0
S C G 0.0the study and the selection of the patient population
[25,32]. Glioblastoma multiforme studies have also con-
firmed that the MNS16A association with the risk of
cancer incidence is highly dependent on the population’s
ethnicity [23,33,34]. Overall, it can be concluded that
there is much controversy regarding the association of
MNS16A with different cancers, which highlights the
importance of cancer origin and ethnicity in the results.ncies of hTERT polymorphisms in breast cancer patients
ient Control OR (95% CI) p
316 0.1423 1.00 -
638 0.2163 0.56 (0.22-1.42 0.220
862 0.1259 0.92 (0.46-1.86) 0.810
064 0.1514 0.50 (0.25-0.99) 0.048
644 0.1047 0.35 (0.16-0.72) 0.005
975 0.0875 0.78 (0.23-2.61) 0.680
630 0.0739 0.41 (0.13-1.26) 0.120
720 0.0385 1.00 (0.18-5.68) 0.970
Table 4 Association between hTERT polymorphisms and clinicopathological characteristics
Variables MNS16A p rs2735940 p rs2736098 p
LL LS SS CC CT TT AA AG GG
Age (years) 0.123 0.181 0.893
≤50 58 83 7 21 70 57 21 82 39
>50 56 48 7 24 52 33 17 57 30
Pathological type 0.812 0.704
Ductal 78 87 10 30 85 60 30 91 45 0.351
Others 37 49 5 15 39 35 10 49 28
Tumor size (cm) 0.429 0.427 0.575
≤2 35 47 6 12 44 32 14 48 19
>2 77 79 7 33 76 54 22 89 46
TNM Stage 0.850 0.237 0.595
I 19 22 3 7 25 12 8 27 8
II 47 48 5 19 41 40 12 51 32
III 32 35 3 14 38 17 12 37 17
IV 13 24 2 5 17 17 4 21 11
Grade 0.437 0.072 0.286
I 23 21 2 10 19 17 10 20 14
II 64 67 7 18 62 58 17 81 34
III 14 30 1 11 26 8 6 22 15
IV 0 0 0 0 1 0 0 0 0
ER status 0.858 0.090 0.260
Positive 68 78 8 26 81 47 23 79 46
Negative 37 43 3 15 32 36 14 47 16
PgR status 0.627 0.620 0.137
Positive 62 79 6 28 71 48 18 80 42
Negative 41 42 5 13 42 33 19 44 20
HER2 status 0.155 0.404 0.186
Positive 50 69 9 27 59 42 15 75 32
Negative 61 59 4 18 60 45 22 59 36
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a significant controversy in association of the variant
and BC risk [35-37]. Haiman et al. [37] observed a
positive association between the 5p15 locus and the in-
creased risk of BC while Savage et al. [35] suggested a
protective effect of three correlated SNPs in this region,
including rs2736098, among Polish women with a
positive family history. For familial cancers, associ-
ation was also observed, although not statistically
significant, after Bonferroni adjustment. In the present
study, we found that the rs2736098 polymorphism
increased the risk of BC in our population, and it can be
concluded that an association between BC risk and hTERT
rs2736098 variant is generally related to ethnicity of the
study population and the geographical location of the
sample.A functional variant located in the promoter of the
hTERT gene, -1327C > T (rs2735940), is associated with
telomere length [38]. There are few reports about the
correlation between the hTERT rs2735940 variant and
BC. Recently, Pellatt et al. found no association between
the hTERT rs2735940 polymorphism and BC risk. They
found that this variant was associated with estrogen re-
ceptor negative/progesterone receptor positive (ER-/PR-)
tumors (OR = 0.73, 95% CI = 0.59-0.91) [39].
Conclusion
Our findings indicate that the MNS16A genotype and
the hTERT rs2736098 variant influence the risk of BC in
an Iranian population in southeast Iran. A limitation of
this study is the relatively small sample size. Further
research on hTERT polymorphisms is required to validate
Hashemi et al. BMC Research Notes 2014, 7:895 Page 7 of 8
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lation and in Middle Eastern countries. Because BC is a
prevalent disease among the female population world-
wide, identifying potential markers that can identify the
possibility of this cancer is of significant importance in
identifying BC in these patients.
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